Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone

References

• Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980–1998. Am. J. Epidemiol.155, 819–826 (2002).
   PubMed Web of Science ®Google Scholar
• Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation108, 711–716 (2003).
   PubMed Web of Science ®Google Scholar
• Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986–1996. Eur. Heart J.22, 693–701 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med.158, 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, Paziaud O, Piot O et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am. Heart J.147, 121–126 (2004).
   PubMed Web of Science ®Google Scholar
• Grönefeld GC, Lilienthal J, Kuck KH, Hohnloser SH; Pharmacological Intervention in Atrial Fibrillation (PIAF) Study investigators. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur. Heart J.24, 1430–1436 (2003).
   PubMed Web of Science ®Google Scholar
• Hagens VE, Ranchor AV, Van Sonderen E et al.; RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J. Am. Coll. Cardiol.43, 241–247 (2004).
   PubMed Web of Science ®Google Scholar
• Levy T, Walker S, Mason M et al. Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study. Heart85, 171–178 (2001).
   PubMed Web of Science ®Google Scholar
• Dorian P, Jung W, Newman D. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J. Am. Coll. Cardiol.36, 1303–1309 (2000).
   PubMed Web of Science ®Google Scholar
• Paquette M, Roy D, Talajic M et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am. J. Cardiol.86, 764–768 (2000).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet356, 1789–1794 (2000).
   PubMed Web of Science ®Google Scholar
• Carlsson J, Miketic S, Windeler J et al.; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol.41, 1690–1696 (2003).
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med.347, 1825–1833 (2002).
   PubMed Web of Science ®Google Scholar
• Opolski G, Torbicki A, Kosior DA et al.; Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest126, 476–486 (2004).
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA et al.; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med.347, 1834–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Singh SN, Tang XC, Singh BN et al.; SAFE-T Investigators. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J. Am. Coll. Cardiol.48, 721–730 (2006).
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med.358, 2667–2677 (2008).
   PubMed Web of Science ®Google Scholar
• Chung MK, Shemanski L, Sherman DG et al.; AFFIRM Investigators. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J. Am. Coll. Cardiol.46, 1891–1899 (2005).
   PubMed Web of Science ®Google Scholar
• Corley SD, Epstein AE, DiMarco JP et al.; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation109, 1509–1513 (2004).
   PubMed Web of Science ®Google Scholar
• Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch. Intern. Med.166, 719–728 (2006).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Withdrawl Public Assessment Report of the Marketing Authorisation Application for Multaq (Dronedarone). European Medicines Agency, Evaluation of Medicines for Human Use, London, UK (2006).
   Google Scholar
• Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann. Pharmacother.41, 599–605 (2007).
   PubMed Web of Science ®Google Scholar
• Tschuppert Y, Buclin T, Rothuizen LE et al. Effect of dronedarone on renal function in healthy subjects. Br. J. Clin. Pharmacol.64, 785–791 (2007).
   PubMed Web of Science ®Google Scholar
• Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J. Cardiovasc. Electrophysiol.17, S17–S20 (2006).
   PubMed Web of Science ®Google Scholar
• Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur. J. Pharmacol.279, 25–32 (1995).
   PubMed Web of Science ®Google Scholar
• Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation100, 2276–2281 (1999).
   PubMed Web of Science ®Google Scholar
• Celestino D, Medei E, Moro S, Elizari MV, Sicouri S. Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study. J. Cardiovasc. Pharmacol. Ther.12, 248–257 (2007).
   PubMed Web of Science ®Google Scholar
• Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J. Cardiovasc. Pharmacol.39, 677–684 (2002).
   PubMed Web of Science ®Google Scholar
• Varró A, Takács J, Németh M et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br. J. Pharmacol.133, 625–634 (2001).
   PubMed Web of Science ®Google Scholar
• Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur. Heart J.24, 1481–1487 (2003).
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ et al.; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med.357, 987–999 (2007).
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C et al.; ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study. Am. Heart J.156, 527.e1–527.e9 (2008).
   PubMed Web of Science ®Google Scholar
• Køber L, Torp-Pedersen C, McMurray JJ et al.; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med.358, 2678–2687 (2008).
   PubMed Web of Science ®Google Scholar
• Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J. Cardiovasc. Electrophysiol.19, 1220–1226 (2008).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C. Rationale and design of ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial Fibrillation/Atrial Flutter. J. Cardiovasc. Electrophysiol.19, 69–73 (2008).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med.360, 668–678 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ. ATHENA: the effect of dronedarone on cardiovascular outcomes and stroke in patients with atrial fibrillation. Clinical trials update 3. Presented at: European Society of Cardiology Congress 2008. Munich, Germany, 3 September 2008.
   Google Scholar